|
|
Article: Helix BioMedix Reports Third Quarter 2009 Financial Results.
- Article from:
- Business Wire
- Article date:
- November 6, 2009
CopyrightCOPYRIGHT 2009 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
BOTHELL, Wash. -- Helix BioMedix, Inc. (OTCBB: HXBM), a developer of bioactive peptides, today announced financial results for the third quarter ended September 30, 2009.
Third quarter 2009 revenue was approximately $98,000 compared to revenue of approximately $138,000 in the second quarter of 2009 and approximately $157,000 in the third quarter of 2008. Gross margins improved to 46.1% in the third quarter 2009, compared to 37.0% in the same period a year ago, primarily due to an increase in higher margin licensing and development fee revenue and a reduction in administrative services revenue.
Net loss for the third quarter of 2009 was approximately ...